Background: The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD). Methods: Subjects had previously responded to atomoxetine acutely and had completed 1 year of double-blind atomoxetine treatment. They were then randomly assigned in double-blind fashion to continued atomoxetine or placebo substitution for 6 months. Results: Atomoxetine was superior to placebo in preventing relapse (Wilcoxon test, p .008) and in maintaining symptom response (ADHD Rating Scale IV score, p.001). Among subjects assigned to discontinuation, the magnitude of symptom return was generally to a level of severity less than that observed at study entry. Conclusions: Following 1 year of treatment with atomoxetine, continued treatment over the ensuing 6 months was associated with superior outcomes compared with placebo substitution. However, there was considerable variability between individuals in the magnitude of symptom return after drug discontinuation, suggesting that some subjects treated with atomoxetine for a year with good results may consolidate gainsmadeduring drug treatment and could benefit from a medication-free trial to assess the need for ongoing drug treatment.
A randomized, double-blind study of continuation treatment for ADHD after one year
ZUDDAS, ALESSANDRO;
2007-01-01
Abstract
Background: The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD). Methods: Subjects had previously responded to atomoxetine acutely and had completed 1 year of double-blind atomoxetine treatment. They were then randomly assigned in double-blind fashion to continued atomoxetine or placebo substitution for 6 months. Results: Atomoxetine was superior to placebo in preventing relapse (Wilcoxon test, p .008) and in maintaining symptom response (ADHD Rating Scale IV score, p.001). Among subjects assigned to discontinuation, the magnitude of symptom return was generally to a level of severity less than that observed at study entry. Conclusions: Following 1 year of treatment with atomoxetine, continued treatment over the ensuing 6 months was associated with superior outcomes compared with placebo substitution. However, there was considerable variability between individuals in the magnitude of symptom return after drug discontinuation, suggesting that some subjects treated with atomoxetine for a year with good results may consolidate gainsmadeduring drug treatment and could benefit from a medication-free trial to assess the need for ongoing drug treatment.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
